Cargando…

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

INTRODUCTION: Circulating tumor cells (CTCs) reflect aggressive tumor behavior by hematogenous tumor cell dissemination. The tissue inhibitor of metalloproteinase 1 (TIMP-1) plays a role in tissue invasion and is also involved in angiogenesis, abrogation of apoptosis and in chemoresistance. Carbonic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Volkmar, Riethdorf, Sabine, Rack, Brigitte, Janni, Wolfgang, Fasching, Peter A, Solomayer, Erich, Aktas, Bahriye, Kasimir-Bauer, Sabine, Zeitz, Julia, Pantel, Klaus, Fehm, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236335/ https://www.ncbi.nlm.nih.gov/pubmed/21745383 http://dx.doi.org/10.1186/bcr2916

Ejemplares similares

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2018)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
por: Fehm, Tanja, et al.
Publicado: (2009)

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
por: Roth, Carina, et al.
Publicado: (2011)

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2009)

Circulating microRNAs: promising breast cancer biomarkers - authors' response
por: Roth, Carina, et al.
Publicado: (2011)

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
por: Roth, Carina, et al.
Publicado: (2010)

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?
por: Polasik, Arkadius, et al.
Publicado: (2017)

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2012)

Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Circulating and Disseminated Tumour Cells in Breast Carcinoma: Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment
por: Bredemeier, Maren, et al.
Publicado: (2016)

Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer
por: Brown-Glaberman, Ursa, et al.
Publicado: (2016)

Evaluation of a novel ELISA for the tumor-associated antigen CA 72–4 in patients with ovarian cancer
por: Buderath, Paul, et al.
Publicado: (2016)

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
por: Rack, Brigitte, et al.
Publicado: (2014)

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer
por: Bredemeier, Maren, et al.
Publicado: (2017)

Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis—Results from the Adjuvant SUCCESS A Trial
por: Trapp, Elisabeth K., et al.
Publicado: (2022)

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
por: Müller, V., et al.
Publicado: (2021)

Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker
por: Ningsi, Retno, et al.
Publicado: (2022)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
por: Schochter, Fabienne, et al.
Publicado: (2020)

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
por: Riethdorf, Sabine, et al.
Publicado: (2009)

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients
por: Stückrath, Isabel, et al.
Publicado: (2015)

Carbonic anhydrase IX in oligodendroglial brain tumors
por: Järvelä, Sally, et al.
Publicado: (2008)

Targeting Carbonic Anhydrase IX Activity and Expression
por: Mahon, Brian P., et al.
Publicado: (2015)

Carbonic Anhydrase IX—Mouse versus Human
por: Takacova, Martina, et al.
Publicado: (2019)

Carbonic anhydrase IX and acid transport in cancer
por: Becker, Holger M.
Publicado: (2019)

Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer
por: Woelber, Linn, et al.
Publicado: (2011)

Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
por: Chebouti, Issam, et al.
Publicado: (2016)

Early increase in circulating carbonic anhydrase IX: A potential new predictive biomarker of preeclampsia
por: Galbiati, Silvia, et al.
Publicado: (2023)

Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma
por: Xiang, An-Ping, et al.
Publicado: (2022)

Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness
por: Ward, Carol, et al.
Publicado: (2018)

Biophysical Characterization of Cancer-Related Carbonic Anhydrase IX
por: Koruza, Katarina, et al.
Publicado: (2020)

Carbonic Anhydrases II, IX, and XII in Reflux Esophagitis
por: Nortunen, Minna, et al.
Publicado: (2021)

Primary Duodenal Adenocarcinoma Expressing Carbonic Anhydrase IX
por: Kubo, Kimitoshi, et al.
Publicado: (2022)

Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma
por: Sim, S H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j754is766ko3aq96kg0otljk5f